{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:31:21Z","timestamp":1776706281948,"version":"3.51.2"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Inhaled epoprostenol is a continuously delivered selective pulmonary vasodilator that is used in patients with refractory hypoxemia, right heart failure, and postcardiac surgery pulmonary hypertension. Published data suggest that inhaled epoprostenol administration via vibrating mesh nebulizer systems may lead to unexpected interruptions in drug delivery. The frequency of these events is unknown. The objective of this study was to describe the incidence and clinical consequences of unexpected interruption in critically ill patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>Retrospective review and analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>Stanford University Hospital, a 605-bed tertiary care center.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>Patients receiving inhaled epoprostenol in 2019.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>INTERVENTIONS:<\/jats:title>\n            <jats:p>No interventions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>Clinical indication, duration of inhaled epoprostenol delivery, mode of respiratory support, and documented unexpected interruption. In 2019, there were 493 administrations of inhaled epoprostenol in 433 unique patients. Primary indications for inhaled epoprostenol were right heart dysfunction (<jats:italic toggle=\"yes\">n<\/jats:italic> = 394; 79.9%) and hypoxemia (<jats:italic toggle=\"yes\">n<\/jats:italic> = 92; 18.7%). Unexpected delivery interruptions occurred in 31 administrations (6.3%). Median duration of therapy prior to unexpected interruption was 2 days (interquartile range, 2\u20135 d). Respiratory support at the time of unexpected interruption was mechanical ventilation (61.3%), high-flow nasal cannula (35.5%), and noninvasive positive pressure ventilation (3.2%). Adverse sequelae of unexpected interruption included elevated pulmonary artery pressures (<jats:italic toggle=\"yes\">n<\/jats:italic> = 12), systemic hypotension (<jats:italic toggle=\"yes\">n<\/jats:italic> = 8), hypoxemia (<jats:italic toggle=\"yes\">n<\/jats:italic> = 8), elevated central venous pressure (<jats:italic toggle=\"yes\">n<\/jats:italic> = 4), and cardiac arrest (<jats:italic toggle=\"yes\">n<\/jats:italic> = 1). Therapeutic interventions following unexpected interruption included initiation of inhaled nitric oxide (<jats:italic toggle=\"yes\">n<\/jats:italic> = 21), increase in vasoactive medication (<jats:italic toggle=\"yes\">n<\/jats:italic> = 2), and increase in respiratory support (<jats:italic toggle=\"yes\">n<\/jats:italic> = 2). Most of the adverse events were Common Terminology Criteria for Adverse Events grade 3 and 4 (93.5%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>A retrospective review of patients receiving inhaled epoprostenol via vibrating mesh nebulizer in 2019 revealed interruptions in 6.3% of administrations with most of these interruptions requiring therapeutic intervention. The true incidence of unexpected interruption and subsequent rate of unexpected interruption\u2019s requiring intervention is unknown due to the reliance on unexpected interruption identification and subsequent documentation in the electronic medical record. Sudden interruption in inhaled epoprostenol delivery can result in severe cardiopulmonary compromise, and on rare occasion, death.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000548","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T09:04:50Z","timestamp":1634634290000},"page":"e0548","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients"],"prefix":"10.1097","volume":"3","author":[{"given":"Jason M.","family":"Block","sequence":"first","affiliation":[{"name":"Department of Anesthesiology, Pain, and Perioperative Medicine, Division of Critical Care Medicine, Stanford University School of Medicine, Stanford, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jai","family":"Madhok","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pain, and Perioperative Medicine, Divisions of Critical Care Medicine and Adult Cardiothoracic Anesthesiology, Stanford University School of Medicine, Stanford, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clark G.","family":"Owyang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary and Critical Care Medicine, New York-Presbyterian\/Weill Cornell Medical Center, New York, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen R.","family":"Merriman","sequence":"additional","affiliation":[{"name":"Department of Respiratory Care Services, Stanford Healthcare, Palo Alto, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Ruoss","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vidya K.","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Pain, and Perioperative Medicine, Divisions of Critical Care Medicine and Adult Cardiothoracic Anesthesiology, Stanford University School of Medicine, Stanford, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,10,14]]},"reference":[{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.jtcvs.2003.11.035","article-title":"Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery.","volume":"127","author":"De Wet","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1067\/mtc.2003.107","article-title":"Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery.","volume":"125","author":"Hach\u00e9","year":"2003","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"287A","DOI":"10.1378\/chest.1119849","article-title":"Effect of inhaled epoprostenol on oxygenation, outcome, and diuresis in critically ill patients.","volume":"140","author":"Peter","year":"2011","journal-title":"Chest"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1378\/chest.14-3161","article-title":"The use of inhaled prostaglandins in patients with ARDS: A systematic review and meta-analysis.","volume":"147","author":"Fuller","year":"2015","journal-title":"Chest"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4187\/respcare.04702","article-title":"Reliability of vibrating mesh technology.","volume":"62","author":"Gowda","year":"2017","journal-title":"Respir Care"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/phar.1365","article-title":"A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome.","volume":"34","author":"Dzierba","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1177\/1060028018776432","article-title":"Effectiveness, safety, and economic comparison of two inhaled epoprostentol products (Flolan and Veletri) in cardiothoracic surgery patients.","volume":"52","author":"Hawn","year":"2018","journal-title":"Ann Pharmacother"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jcrc.2013.03.006","article-title":"Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients.","volume":"28","author":"Torbic","year":"2013","journal-title":"J Crit Care"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jtcvs.2009.04.063","article-title":"A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients.","volume":"138","author":"Khan","year":"2009","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1053\/j.jvca.2007.10.015","article-title":"Comparison of inhaled iloprost and nitric oxide in patients with pulmonary hypertension during weaning from cardiopulmonary bypass in cardiac surgery: A prospective randomized trial.","volume":"22","author":"Winterhalter","year":"2008","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.jvca.2017.12.014","article-title":"Inhaled nitric oxide (iNO) and inhaled epoprostenol (iPGI2) use in cardiothoracic surgical patients: Is there sufficient evidence for evidence-based recommendations?","volume":"32","author":"Rao","year":"2018","journal-title":"J Cardiothorac Vasc Anesth"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T15:07:07Z","timestamp":1723043227000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000548","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}